Literature DB >> 9458167

Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression.

W S Griffin1, J G Sheng, M C Royston, S M Gentleman, J E McKenzie, D I Graham, G W Roberts, R E Mrak.   

Abstract

The role of glial inflammatory processes in Alzheimer's disease has been highlighted by recent epidemiological work establishing head trauma as an important risk factor, and the use of anti-inflammatory agents as an important ameliorating factor, in this disease. This review advances the hypothesis that chronic activation of glial inflammatory processes, arising from genetic or environmental insults to neurons and accompanied by chronic elaboration of neuroactive glia-derived cytokines and other proteins, sets in motion a cytokine cycle of cellular and molecular events with neurodegenerative consequences. In this cycle, interleukin-1 is a key initiating and coordinating agent. Interleukin-1 promotes neuronal synthesis and processing of the beta-amyloid precursor protein, thus favoring continuing deposition of beta-amyloid, and activates astrocytes and promotes astrocytic synthesis and release of a number of inflammatory and neuroactive molecules. One of these, S100beta, is a neurite growth-promoting cytokine that stresses neurons through its trophic actions and fosters neuronal cell dysfunction and death by raising intraneuronal free calcium concentrations. Neuronal injury arising from these cytokine-induced neuronal insults can activate microglia with further overexpression of interleukin-1, thus producing feedback amplification and self-propagation of this cytokine cycle. Additional feedback amplification is provided through other elements of the cycle. Chronic propagation of this cytokine cycle represents a possible mechanism for progression of neurodegenerative changes culminating in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458167     DOI: 10.1111/j.1750-3639.1998.tb00136.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  191 in total

1.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

Authors:  Y Matsuoka; M Picciano; B Malester; J LaFrancois; C Zehr; J M Daeschner; J A Olschowka; M I Fonseca; M K O'Banion; A J Tenner; C A Lemere; K Duff
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk.

Authors:  W S Griffin; J A Nicoll; L M Grimaldi; J G Sheng; R E Mrak
Journal:  Exp Gerontol       Date:  2000-07       Impact factor: 4.032

3.  Changes in APP, PS1 and other factors related to Alzheimer's disease pathophysiology after trimethyltin-induced brain lesion in the rat.

Authors:  Camilla Nilsberth; Beata Kostyszyn; Johan Luthman
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

4.  Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo.

Authors:  J G Sheng; S G Zhu; R A Jones; W S Griffin; R E Mrak
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

5.  The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study.

Authors:  K S Benke; M C Carlson; B Q Doan; J D Walston; Q L Xue; A P Reiner; L P Fried; D E Arking; A Chakravarti; M D Fallin
Journal:  Exp Gerontol       Date:  2011-09-24       Impact factor: 4.032

Review 6.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 7.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Periodontal disease associates with higher brain amyloid load in normal elderly.

Authors:  Angela R Kamer; Elizabeth Pirraglia; Wai Tsui; Henry Rusinek; Shankar Vallabhajosula; Lisa Mosconi; Li Yi; Pauline McHugh; Ronald G Craig; Spencer Svetcov; Ross Linker; Chen Shi; Lidia Glodzik; Schantel Williams; Patricia Corby; Deepak Saxena; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2014-11-05       Impact factor: 4.673

9.  Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression.

Authors:  Krista M Rodgers; Yuetiva K Deming; Florencia M Bercum; Serhiy Y Chumachenko; Julie L Wieseler; Kirk W Johnson; Linda R Watkins; Daniel S Barth
Journal:  J Neurotrauma       Date:  2013-11-20       Impact factor: 5.269

10.  The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.

Authors:  G P Lim; T Chu; F Yang; W Beech; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.